The poster, titled Development of new gamma-secretase modulators for the treatment of Alzheimer’s diseasewas presented by Dr.
The presentation included data on the effects of AC-0027875, a potent new compound of the Alzstatin platform, on the reduction of Aβ42 in cells and animals.
AC-0027875 effectively reduced Aβ42 production in cells and lowered Aβ42 in brain in a time-dependent manner. The compound has also displayed good pharmacokinetic properties and further studies with the compound are currently underway.
“Aggregation of the toxic beta-amyloid, Aβ42, leads to the formation of amyloid plaques – a process that plays a central role in the early pathogenesis of Alzheimer’s disease. Modulators of γ-secretase, called GSM, represent a promising class of Aβ42-lowering anti-amyloidogenic compounds that differentiates itself from antibody therapies and our compounds in Alzstatin are prime examples,” said Martin Jönsson, CEO of
The presentation, the poster and the summary are available on the AlzeCure website: (https://www.alzecurepharma.se/en/presentations-and-interviews/).